Dov A Goldstein Md sold $532k of BIOA
Chief Financial Officer at BioAge Labs, Inc.. 27,000 shares at an average of $19.70, traded Jan 13, 2026, filed Jan 15, 2026.
Score components
- +22RoleCFO
- +18Trade size$532k at market
- +20Share of holdings soldSold 55% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -9.0%, 3m -21.0%, 6m +3.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001120478-26-000003, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 13, 2026 | MOption exercise Common Stock10b5-1 | +27,000 | $8.39 | $227k | 49,408 | Jan 15, 2026 |
| Jan 13, 2026 | SOpen-market sale Common Stock10b5-1 | -8,974 | $18.43 | $165k | 40,434 | Jan 15, 2026 |
| Jan 13, 2026 | SOpen-market sale Common Stock10b5-1 | -4,440 | $19.45 | $86k | 35,994 | Jan 15, 2026 |
| Jan 13, 2026 | SOpen-market sale Common Stock10b5-1 | -11,663 | $20.54 | $240k | 24,331 | Jan 15, 2026 |
| Jan 13, 2026 | SOpen-market sale Common Stock10b5-1 | -1,923 | $21.08 | $41k | 22,408 | Jan 15, 2026 |
| Jan 13, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -27,000 | $0.00 | $0 | 92,587 | Jan 15, 2026 |
Related signals
Other insiders at BioAge Labs, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | BioAge Labs, Inc. | Shane Barton Principal Accounting Officer | $1.6M 62,566 shares | -148% | |
| 11Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $157k 8,820 shares | -100% | |
| 11Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $151k 7,433 shares | -100% | |
| 11Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $139k 7,433 shares | -100% | |
| 50Moderate | BioAge Labs, Inc. | Kristen Fortney Chief Executive Officer | $4.2M 233,107 shares | -19% | |
| 25Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $95k 7,433 shares | -100% | |
| 12Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $216k 18,000 shares | -100% | |
| 21Weak | BioAge Labs, Inc. | Paul D Rubin Chief Medical Officer | $702k 68,897 shares | -100% | |
| 29Weak | BIOAbuy BioAge Labs, Inc. | Shane Barton Principal Accounting Officer | $47k 2,632 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.